Drugs / CRD3874
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06626633 | Aug 2024 → Aug 2025 | acute myeloid leukemia | University of Maryland, Baltimore | Suspended | No outcome recorded |
| Phase 1 | NCT06021626 | Aug 2023 → Aug 2029 expected | cutaneous neuroendocrine carcinoma, sarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRD3874 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06021626 ↗ |
| Known as | CRD3874-SI | “Drug Product: CRD3874 solution for injection (CRD3874-SI)” NCT06626633 ↗ |
| Action | Activate | “a STING Agonist” NCT06021626 ↗ |
| Modality | Small molecule | “Type of drug: Synthetic small molecule” NCT06626633 ↗ |
| Route | Intravenous | “weekly IV infusion” NCT06021626 ↗ |